Latest News and Press Releases

Geneva, Switzerland, 8 December 2022 -- iOnctura SA a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways,...

Geneva, Switzerland, 27 September 2022 -- iOnctura SA, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways,...

GENEVA, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical-stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, has...

GENEVA, March 09, 2022 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical-stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, will present...

GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is...

GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is...

GENEVA, Nov. 23, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces it will...

GENEVA, Switzerland, Nov. 12, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, presented...

Expansion of DIONE-01 supports subsequent transition to registration studies in metastatic uveal melanomaDIONE-01 trial design expanded with multiple cohorts including solid and hematologic...

GENEVA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces that it will...